On the basis of evidence described in this study and the favorable phase I safety profile, oral OLT1177 has advanced into three phase II development programs, including gout, establishing the translational value of OLT1177 as a safe oral NLRP3 inhibitor. This evidence concerns the gene NLRP3 and gout.